Analytical Data
-
Gene name
p65
- Application
-
Species
Mycoplasma pneumoniae
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0CJ81
-
Expression Region
1-405aa
-
Molecular Weight
54.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The P65 recombinant protein is derived from the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, which plays a crucial role in regulating immune responses, inflammation, and cell survival. NF-κB is a transcription factor that, upon activation, translocates to the nucleus to modulate gene expression related to these biological processes. P65, also known as RelA, is one of the key subunits of NF-κB and is essential for its transcriptional activity. Research on P65 recombinant protein has gained significance due to its involvement in various pathological conditions, such as cancer, autoimmune diseases, and chronic inflammatory disorders. The ability to produce P65 in a recombinant form allows for detailed studies of its structure-function relationship and post-translational modifications, which are crucial for its activity. Additionally, P65 recombinant protein is a valuable tool in drug discovery and therapeutic applications, as it can be used to screen potential inhibitors that modulate NF-κB activity. Understanding the precise mechanisms by which P65 influences cellular processes also provides insights into novel therapeutic strategies for targeting diseases characterized by dysregulated NF-κB signaling, highlighting the importance of ongoing research in this area.
